Speaker
Summary
The β- emitter 111-Ag (half-life = 7.45 days) is a promising candidat for theapry due to its medium tissue penetration of around 1.8 mm. Furthermore, its gamma rays at 245 keV and 342 keV might be used for SPECT imaging to survey the treatment and the in-vivo dose delivered to the patient. Several production routes have been studied and there is notably the alpha route natPd(a,x)111Ag which lacks experimental data. New cross section measurements were thus performed at GIP ARRONAX using an alpha beam of 67.4 MeV to define better the maximum cross section and what's happening after. These new data, combined with the long-lived silver contaminant cross sections, enable the optimization of production parameters for 111Ag and allow for comparisons with the other production routes in terms of yield, purity, and specific activity.
| Are you interested/eligible for the Young Session? | Yes, I am eligible and interested in participating |
|---|
